NuvemRx has acquired par8o, an R1 company, for an undisclosed amount. This corporate acquisition sees NuvemRx taking ownership of Cloudmed 340B Recovery, previously known as par8o, a specialized solution designed to optimize savings within the federal 340B drug pricing program. The transaction marks a significant move for NuvemRx to expand its footprint and capabilities in the healthcare technology sector, specifically targeting the intricate landscape of pharmaceutical cost recovery.
par8o's core offering, Cloudmed 340B Recovery, focuses on identifying and recovering 340B savings from misclassified scripts through ineligible claim and referral capture. Its compliance-first solution is engineered to integrate seamlessly with various third-party administrators (TPAs) and contract pharmacies. A key differentiator for par8o is its favored integration with the top two retail pharmacy chains, enabling it to uncover savings that other systems might miss, thereby maximizing financial recovery for eligible healthcare entities.
The acquisition is strategically aimed at bolstering NuvemRx's portfolio by integrating par8o's proven technology and deep expertise in 340B savings recovery. By incorporating par8o's robust platform and its strong pharmacy network integrations, NuvemRx is positioned to offer a more comprehensive and efficient suite of solutions to its clients. This synergy is expected to enhance NuvemRx's ability to navigate the complexities of 340B compliance and optimization, providing greater value through improved financial performance and operational efficiency for covered entities.
Looking ahead, the combined entity is expected to deliver advanced tools and services that streamline 340B program management, improve compliance, and significantly increase savings recovery for healthcare providers. This integration will allow NuvemRx to offer an expanded and more powerful solution, reinforcing its commitment to supporting healthcare organizations in maximizing their resources and ensuring program integrity within the evolving pharmaceutical landscape.